(ACN Newswire) – The Lubrizol Corporation’s LifeSciences business is investing $15 million to expand its global manufacturing facilities, positioning LifeSciences to better serve the growing market for medical device contract manufacturing.
Since 2014, Lubrizol LifeSciences has solidified its presence in the life sciences market by introducing new products and making strategic acquisitions. This capital investment will expand multiple facilities and increase Lubrizol LifeSciences’ in-house engineering capacity for both silicone and thermoplastic products.
“We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class component manufacturing,” states Deb Langer, vice president and general manager, Lubrizol LifeSciences. “As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings to our customers.”
Vesta, Inc., acquired by Lubrizol in August of 2014, is a leading contract manufacturer for the global medical device industry. With the addition of Vesta, Lubrizol LifeSciences now offers disposable and implantable silicone medical components and assemblies across a wide product portfolio, as well as precision thermoplastic extruded tubing. The recent acquisition of Particle Sciences, Inc., a leading contract drug development and manufacturing organization, has positioned Lubrizol LifeSciences as one of the most comprehensive drug delivery device solution providers, offering end-to-end solutions in the healthcare market.
“When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process,” states Robert Miller, global business director, medical devices. “With a long history of polymer expertise and significant investment, Lubrizol LifeSciences is positioned to offer full-service development for next generation medical and pharmaceutical innovations.”
Source: The Lubrizol Corporation
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
